Navigation Links
The Galien Foundation Honors Excellence in Scientific Innovation and Humanitarian Efforts at 2013 Prix Galien USA Awards Gala

NEW YORK, Oct. 23, 2013 /PRNewswire/ -- The Prix Galien USA Awards Committee last night honored excellence in research, development and innovation in the biopharmaceutical industry at its seventh annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. Led by Dr. P. Roy Vagelos, and comprised of an unrivaled network of nine esteemed individuals in the biomedical industry and academia, including five Nobel Laureates, the Galien Awards Committee recognized leading efforts in advancing the welfare of humankind in three categories: best biotechnology product, best pharmaceutical agent, and best medical technology.


Prix Galien USA 2013 Award winners were Boston Scientific's S-ICD® System (subcutaneous implantable defibrillator), for best medical technology product; Genentech's Zelboraf® (vemurafenib), for best pharmaceutical agent; and Merck's Zostavax® (Zoster Vaccine Live), for best biotechnology product.

"Biomedical research cannot advance without professionals in the medical field who are constantly seeking to understand, constantly innovating, and constantly dedicated to improving the welfare of patients everywhere,"  remarked Dr. Vagelos. "This year's winners, and indeed all of our nominees, are leading the way in developing disease-altering advancements through biopharmaceutical innovation. Because of our focus on recognizing the devoted, brilliant teams and individuals who bring about breakthroughs in the development and discovery of products that improve the human condition, the Prix Galien USA Awards continue to be the beacon of industry honors."

In the category of Best Medical Technology Product, the 2013 Prix Galien USA Award was presented to Boston Scientific's S-ICD System (subcutaneous implantable defibrillator), the world's first and only subcutaneous implantable defibrillator that utilizes a pulse generator capable of delivering life-saving high-energy shocks to patients suffering from episodes of ventricular fibrillation and ventricular tachycardia. The innovative S-ICD System uses groundbreaking technology to identify and classify the heart rhythm as a whole rather than in individual beats, which aids in sensing, discriminating, and converting abnormal heartbeats. Unlike transvenous ICDs, the S-ICD System is implanted in the lateral thoracic region of the body and utilizes a subcutaneous electrode instead of transvenous leads to both sense and deliver therapy, eliminating potential for vascular injury and reducing potential for systemic infection as well as radiation exposure in patients.

The 2013 Prix Galien USA Award for Best Pharmaceutical Agent was presented to Genentech's Zelboraf (vemurafenib), a prescription medicine used to treat late-stage melanoma that has metastasized to other parts of the body or cannot be removed by surgery, and that has a BRAF V600E mutation. Zelboraf has been approved by the FDA, Health Canada, and the European Commission.

The 2013 Prix Galien USA Award for Best Biotechnology Product was awarded to Merck's Zostavax (Zoster Vaccine Live). Zostavax is an FDA-licensed vaccine that helps to reduce the risk of contracting the viral disease herpes zoster (shingles) in individuals 50 years of age and older. Zostavax is the only US-licensed vaccine that reduces the risk of reactivation of the varicella zoster virus, the virus that causes chicken pox and remains dormant in the body even after recovery.

About the Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information visit

Galien Foundation Media Contact:
Jon Florio

SOURCE Galien Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Galien Foundation Celebrates Biomedical Innovation in Fourth Galien Forum
2. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
3. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
4. Agile and Scrum Workshop – Values, Foundations, and Practices in San Diego, CA by Conscires Agile Practices
5. “Agile and Scrum – Values, Foundations, and Practices” in Philadelphia, PA- 8 PDUs
6. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
7. Bayer CropScience and the Florida Specialty Crop Foundation Join Together to Fight Citrus Greening
8. La Allotrope Foundation se asocia con Osthus Inc.
9. Allotrope Foundation partners with Osthus Inc. to develop state-of-the-art open framework for laboratory data
10. Chicago Mayor Rahm Emmanuel and Illinois Governor Patrick Quinn Recognize Brain Research Foundations 60th Anniversary
11. Avon Foundation for Women, NIH, and the Center for Advancing Innovation Launch Start-Up Challenge to Advance Breast Cancer Biomedical Invention
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):